Search Results

You are looking at 31 - 40 of 110 items for :

  • Refine by Access: All x
Clear All
Full access

Matthew A. Gubens

Conference. “Immunotherapy is not a new idea. It was proposed by William B. Coley, MD, in 1893 as a treatment for cancer. Today, we have immunotherapies directed against PD-1 [programmed death], PD-L1 [programmed death ligand-1], and CTLA-4,” he stated

Full access

Toni K. Choueiri and Robert J. Motzer

immune checkpoint blockade. One study reported on 44 patients (80% of whom had received prior systemic agents) treated with nivolumab plus ipilimumab, the latter being a CTLA-4 blocker; CTLA-4 is another distinct checkpoint on the immune cell. The median

Full access

Xiuning Le, Renata Ferrarotto, Trisha Wise-Draper, and Maura Gillison

. For example, CTLA-4 is another immune checkpoint protein that is expressed on T cells (mostly T-regulatory cells) to downregulate immune responses and mediates tumor immune escape. 32 – 34 Furthermore, anti–CTLA-4 in addition to anti–PD-1/L1 has been

Full access

Daniel G. Coit, John A. Thompson, Alain Algazi, Robert Andtbacka, Christopher K. Bichakjian, William E. Carson III, Gregory A. Daniels, Dominick DiMaio, Ryan C. Fields, Martin D. Fleming, Brian Gastman, Rene Gonzalez, Valerie Guild, Douglas Johnson, Richard W. Joseph, Julie R. Lange, Mary C. Martini, Miguel A. Materin, Anthony J. Olszanski, Patrick Ott, Aparna Priyanath Gupta, Merrick I. Ross, April K. Salama, Joseph Skitzki, Susan M. Swetter, Kenneth K. Tanabe, Javier F. Torres-Roca, Vijay Trisal, Marshall M. Urist, Nicole McMillian, and Anita Engh

modulated by other receptor-ligand interactions between the 2 cells. Cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed cell death protein-1 (PD-1) are 2 examples of receptors on T cells that, upon ligand binding, trigger a signaling cascade that

Full access

Presenter: Javid J. Moslehi

patients treated with combination ICI (anti–CTLA-4 and anti–PD-1) therapy. It develops early in the course of treatment and is unpredictable. Early analysis shows a 50% mortality for this fulminant condition. The main risk factor we can identify is the

Full access

Margaret Tempero

patient wants to know more? That alone might eliminate several pages from each document. Another example is the risk associated with checkpoint inhibitors, such as CTLA-4 inhibitors or PD-1 or PD-L1 inhibitors. The last consent document I looked at

Full access

Jun Gong, Chongkai Wang, Peter P. Lee, Peiguo Chu, and Marwan Fakih

, 14 To counteract the increase in infiltrating immune cells, POLE -mutated and MSI tumors (hypermutated phenotype) upregulate expression of immune checkpoints, including PD-1, PD-L1, and CTLA-4, as evidenced in our case; this phenomenon renders these

Full access

progressing on or following prior treatment (that did not include a checkpoint inhibitor like PD-1i, PDL-1i, or CTLA4i) and who have no satisfactory alternative treatment options. Prior use of immuno-oncology therapy in these patients will make them

Full access

Leslie A. Fecher, Shrinivas Bishu, Robert J. Fontana, Salim S. Hayek, and Bryan J. Schneider

Treatment with immune checkpoint inhibitors (ICIs) continues to transform oncology and includes antibodies against CTLA-4, PD-1, and PD-L1. Anticancer benefit has been shown across multiple solid tumor malignancies as well as in some hematologic

Full access

Rachel A. Bender Ignacio, Lilie L. Lin, Lakshmi Rajdev, and Elizabeth Chiao

inhibitor alone or in combination with a CTLA-4 inhibitor. In addition, 5 of the lymphoma studies evaluated gene-modified stem cell trials with or without cytotoxic chemotherapy, with 1 phase I/II allogeneic Epstein-Barr virus (EBV)–specific cytotoxic T